Dr. Gerald W Dryden, MD, Ph.D
Claim this profileUniversity Of Louisville
Studies Inflammatory Bowel Disease
Studies Ulcer
10 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Gerald W Dryden, MD, Ph.D is currently running
Ozanimod
for Ulcerative Colitis
The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.
Recruiting4 awards Phase 4
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106. All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg open label treatment arms (Part #2) depending on their clinical response at the end of induction. This study consists of a 44-week treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
Recruiting1 award Phase 3
More about Gerald W Dryden, MD, Ph.D
Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Gerald W Dryden, MD, Ph.D has experience with
- CC-93538
- Placebo
- ABX464
- Ozanimod
- Cendakimab
- CYP Substrates
Breakdown of trials Gerald W Dryden, MD, Ph.D has run
Inflammatory Bowel Disease
Ulcer
Ulcerative Colitis
Eosinophilic Esophagitis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gerald W Dryden, MD, Ph.D specialize in?
Gerald W Dryden, MD, Ph.D focuses on Inflammatory Bowel Disease and Ulcer. In particular, much of their work with Inflammatory Bowel Disease has involved treating patients, or patients who are undergoing treatment.
Is Gerald W Dryden, MD, Ph.D currently recruiting for clinical trials?
Yes, Gerald W Dryden, MD, Ph.D is currently recruiting for 6 clinical trials in Louisville Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Gerald W Dryden, MD, Ph.D has studied deeply?
Yes, Gerald W Dryden, MD, Ph.D has studied treatments such as CC-93538, Placebo, ABX464.
What is the best way to schedule an appointment with Gerald W Dryden, MD, Ph.D?
Apply for one of the trials that Gerald W Dryden, MD, Ph.D is conducting.
What is the office address of Gerald W Dryden, MD, Ph.D?
The office of Gerald W Dryden, MD, Ph.D is located at: University Of Louisville, Louisville, Kentucky 40202 United States. This is the address for their practice at the University Of Louisville.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.